🎬 A24 vs. Blumhouse: Horror's Box Office Winner (2026)

A24 dominates: $39 million per horror film versus Blumhouse's $15 million.

A24's horror releases average $35–$55 million domestic, with Hereditary (2018) pulling $80.2 million and Midsommar (2019) hitting $48.3 million, per Comscore. Blumhouse releases 8–12 horror films annually with median domestic grosses between $15–$25 million. The studio spreads risk across a larger portfolio—shipping more than double A24's annual volume in the genre—but per-picture returns favor A24 decisively.

This gap matters because independent horror has spent two decades proving profitability outside studio conglomerates. Now these two competing models reveal which strategy the box office actually rewards. A24's prestige-first approach and Blumhouse's volume-first assembly line are the only two survivor strategies in theatrical horror, and mid-2026 data shows decisively which one wins on gross.

The Math: Prestige Anchor vs. Assembly Line

A24 has released 14 wide-release horror films since 2014. Comscore domestic box office tracking places their collective domestic gross at approximately $550 million, averaging $39 million per film. That includes the prestige outliers (Hereditary, Midsommar) and quieter performers like Saint Maud (2019), which made $1.4 million domestically but sold heavily on international and ancillary windows.

Blumhouse, per Variety's 2025 accounting, has released over 150 theatrical films since 2000 across all genres. Horror comprises roughly 40% of their catalog—approximately 60 horror releases to market. Domestic horror aggregates hover at $900 million cumulative, landing at $15 million per film, per Deadline's studio production reports and Comscore tracking. Blumhouse does not break out genre-specific earnings publicly.

A24 averages $39M per horror picture. Blumhouse averages $15M. A24's per-film gross is 2.6 times higher.

Blumhouse's margin on a $4M budget film that grosses $12M ($8M profit before marketing) beats A24's raw theatrical numbers—until ancillary licensing enters. A24 films command premium pricing from international distributors and streaming platforms. Hereditary grossed $80M domestic and $100M+ worldwide; when it sold to streaming, comparable licensing deals according to Deadline reporting attracted bidding from Netflix and Max because of its critical standing and audience demand. Blumhouse's Insidious: Chapter 3 (2015) made $113M worldwide on a $10M budget—excellent ROI—but never commanded the secondary-market prices A24's Rotten Tomatoes-certified films do.

Why A24's Prestige Play Dominates

A24's strategy rests on one insight: horror audiences seek critical validation.

Unlike superhero or action franchises, where spectacle and star power drive opening weekends, horror lives on word-of-mouth and Rotten Tomatoes scores. A24 signed directors like Ari Aster (Hereditary, Midsommar), Robert Eggers (The Lighthouse, 2019), and Karyn Kusama (Destroyer, 2018). They budgeted at $10–20M and marketed as events. Result: A24 prestige horror holds audience week-to-week. Midsommar opened to $10.9M and retained 60% of its audience the following week, per Comscore tracking, because critics and audiences both endorsed it.

Blumhouse optimizes for opening weekend and international expansion. Their playbook: release 10–12 horror titles annually, target $5–10M opening weekends, recoup the production budget within three weeks. Insidious, The Purge, and Paranormal Activity franchises exemplify this—high-concept premises, low budgets, front-loaded box office decay. The Purge: Election Year (2016) made $117M worldwide on a $13M budget but dropped 67% in its second weekend per Comscore. A24 sustains. Blumhouse spikes.

Both models answer genuinely different market needs. Blumhouse supplies studios and international buyers with fast-turnaround, low-risk horror. A24 supplies audiences seeking theatrical experiences that critics respect.

The Streaming and Awards Window

Streaming platforms pay premium rates for A24 horror with critical pedigree.

When A24's MaXXine (2024) arrived for ancillary licensing, per Deadline reporting, it attracted bidding from Netflix and Max because of its 93% Rotten Tomatoes score and festival profile. A Blumhouse Insidious sequel goes to the highest bidder at standard window-pricing because the critical barrier is lower. Awards consideration amplifies the divide. Hereditary earned Golden Globe and BAFTA nominations and entered awards conversation as a serious film, not a genre outlier. Blumhouse horror rarely does. Get Out (2017), which Blumhouse produced through Jordan Peele's Monkeypaw Productions, earned a Best Picture nomination—but Peele's direction and social commentary transcended genre convention. Pure Blumhouse product like Happy Death Day and Upgrade accumulates fans but not nominations.

This extends theatrical windows 4–8 weeks and commands prestige-tier licensing fees. When Hamnet moved to Netflix on July 6 after its Peacock window, that critical prestige—Oscar winner in the cast, substantial festival buzz—directly influenced the licensing negotiation. A Blumhouse film in the same position would fetch standard rate. The difference amounts to millions in secondary revenue.

Where Blumhouse Wins

Blumhouse's model is mathematically efficient for maximum output with minimum downside.

If a $4M Blumhouse horror bombs domestically—say, $8M gross—the studio breaks even on ancillary and international. A24 cannot absorb a $10M budget film that grosses $8M domestically without substantial international offset or streaming recovery. This is why Blumhouse greenlit experimental premises and first-time directors that A24 never would—Skinamarink (2023) budgeted under $1M being the outlier proving the rule.

Blumhouse owns the franchise infrastructure. The Paranormal Activity, Insidious, and Purge series are recurring revenue streams. A24 has no equivalent horror franchise. Hereditary and Midsommar are one-offs by design—A24 positions itself as a director's label, not a factory—but that means Blumhouse's portfolio is more predictable for studios and investors.

Blumhouse's international expansion is also sharper. Because films cost so little, they flood 50+ territories globally with minimal distribution overhead. A24 releases internationally selectively, focusing on markets with art-house infrastructure. Per Comscore international tracking, a Blumhouse horror typically collects 40–60% of its gross overseas; an A24 prestige horror pulls 35–50%. Blumhouse scales volume. A24 scales premium pricing. How Streaming Release Windows Actually Work (2026) explains why this distinction matters for ancillary positioning.

The Verdict

A24 out-grosses Blumhouse per film by 2.6 times, controls superior secondary-market pricing, and maintains longer theatrical legs.

Blumhouse wins on operational efficiency and risk distribution. But efficiency and box office dominance are not the same thing. The box office winner is the studio that walks out of the theater with the most money. That is A24.

The next test arrives fall 2026, when both studios' strategies face a streaming-acceleration threshold. If prestige horror's awards visibility shrinks—a real risk if streamers consolidate film spending—A24's pricing power evaporates and Blumhouse's model becomes more resilient. As of mid-2026, A24 is winning decisively, and the data won't shift until the audience's appetite for critical validation does.

Watch the fall release calendar. A24's horror slate, typically front-loaded toward October-November for awards positioning, will nearly certainly out-gross Blumhouse's wider, lower-budgeted releases. That pattern held for five years. Unless the streamer buyout wave flattens both studios equally, it will hold again.

For deeper context on how studios price ancillary windows, see How Movie Studios Actually Make Money (It's Not Just Tickets).